The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NY-ESO-1 as a predictive marker for neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer (NSCLC).
T. John
No relevant relationships to disclose
Y. Chen
No relevant relationships to disclose
M. H. Starmans
No relevant relationships to disclose
M. Walkiewicz
No relevant relationships to disclose
P. Russell
No relevant relationships to disclose
A. Azad
No relevant relationships to disclose
S. Deb
No relevant relationships to disclose
N. K. Altorki
No relevant relationships to disclose
P. C. Boutros
No relevant relationships to disclose
P. Mitchell
No relevant relationships to disclose
J. S. Cebon
No relevant relationships to disclose